Open Access
Article

Prognostic gene profiles in the tumor microenvironment of ovarian serous adenocarcinoma

Ruyue Tian1,Guiping Zhao2,Anni Zhou2,Huihui Li1,Bangwei Cao1,Shuilong Guo2,*
1
Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
2
Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing, 100050, China
DOI: 10.2741/4913 Volume 26 Issue 4, pp.692-705
Published: 01 October 2020
(This article belongs to the Special Issue Leader sequences of coronavirus are altered during infection)
*Corresponding Author(s):  
Shuilong Guo
E-mail:  
slong.guo@163.com
Abstract

Ovarian serous adenocarcinoma is one of the most common and fatal malignancies among women worldwide. The tumor microenvironment plays a critical role in tumor initiation, proliferation, and metastasis. Immune scores and stromal scores of the tumor microenvironment were determined using the ESTIMATE. Immune cell infiltration was assessed using TIMER and differentially expressed genes (DEGs) were determined using the R/Bioconductor package of edgeR. Survival analysis was carried out using a univariate Cox model and Kaplan-Meier survival, and gene functional information was obtained through Gene Ontology and KEGG pathway analysis. Survival analysis revealed 39 DEGs that significantly influenced the prognosis of ovarian serous adenocarcinoma patients and were correlated with immune cell abundance. Functional enrichment and protein-protein interaction network analyses further indicated that these genes are primarily involved in immune-related responses. Finally, we verified the prognostic value of these genes via GEO. The present results reveal the genes associated with the tumor microenvironment of ovarian adenocarcinoma, potentially providing prognostic information.

Key words

Gene Expression Omnibus, The Cancer Genome Atlas, tumor microenvironment, prognosis, ovarian serous adenocarcinoma

2. Introduction

Ovarian cancer (OC) is one of the common and fatal malignancies among women worldwide (1). Ninety percent of ovarian cancers are epithelial, the most common being serous carcinoma, for which accounts for 52% of all cases (2). Despite advancements in the diagnosis and treatment of serous ovarian cancer, the mortality rate remains high owing to the lack of specific early symptoms and effective detection methods (2). Gene expression analysis based on TCGA data has reported that ovarian serous adenocarcinoma is primarily of four subtypes: proliferative, mesenchymal, immunoreactive, and differentiated; the immunoreactive subtype has a better prognosis (3-4). Clinical trials have revealed the potential of immunotherapy to improve the prognosis of patients. However, most of these studies are still in the preliminary stage, and patients administered immunotherapy may experience different adverse reactions (5-7). Hence, it is important to establish accurate and effective biomarkers to develop early detection and immunotherapeutic methods to treat ovarian serous adenocarcinoma.

Previous studies have reported that aberrantly expressed genes in tumor tissues potentially serve as prognostic biomarkers for numerous cancers including gastric cancer, colorectal cancer, and cutaneous melanoma (8-10). Moreover, these genes are regulated by the tumor microenvironment (TME). The TME, comprising tumor cells, immune cells, and non-immune cells (including endothelial cells and stromal cells), plays an important role in tumorigenesis (11). TME analysis has become the basis of predicting treatment responses, and the TME algorithm, ESTIMATE, has been recently developed (12) to assess immune and stromal cell infiltration levels in tumor tissues, using two enrichment scores: one based on immune-related genes, called the “immune” score; the other is determined on the basis of non-immune genes, called the “stromal” score.

This study focused on the genetic characteristics of the TME for ovarian serous adenocarcinoma. Based on the integration of immune and stromal scores of TME with immune cells and genes, we extracted some TME-related genes, which are associated with immune cell infiltration and the prognosis of ovarian serous adenocarcinoma patients. Cross-validation of large samples in TCGA and GEO databases would provide robust evidence regarding such gene expression profiles. Therefore, this study may reveal the predictive potential of previously unreported genes.

3. Materials and Methods

3.1. Data sources

Level 3 gene expression profiles (level 3 data) of OC patients up to July 18, 2019 were obtained from TCGA data portal (https://tcga-data.nci.nih.gov/tcga/) and quantified using Affymetrix HT-HG-U133A. Patient clinical characteristics including sex, age, histological type, stage, subtypes, and survival were also downloaded from TCGA. All 469 OC patients were ovarian serous adenocarcinoma Immune scores and stromal scores were determined using ESTIMATE (https://bioinformatics.mdanderson.org/estimate/) data. For validation, expression profiling of OC patients performed in accordance with the Gene Expression Omnibus (GEO) database (GSE9891, GSE26712, and GSE17260, up to August 29, 2019), with 573 patients with reported survival times and outcomes.

3.2. Analysis of immune cell infiltration and differentially expressed genes (DEGs)

The abundance of six types of immune cells, ie, B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells, and their association with the survival of ovarian serous adenocarcinoma patients were determined using TIMER up to July 18, 2019 (https://cistrome.shinyapps.io/timer/). To verify the accuracy of the evaluation scores, we divided ovarian serous adenocarcinoma patients into high-score and low-score groups in accordance with the median score, and the cell infiltration and DEGs were determined in these groups. Differential mRNA expression levels in ovarian serous adenocarcinoma (high-score and low-score groups) were determined using R/Bioconductor package of edgeR. A fold change > 2, p-value < 0.05 were set as the cutoffs for significantly DEGs. TIMER uses a previously reported statistical method to infer the abundance of tumor-infiltrating immune cells (TIICs) on the basis of gene expression profiles. A correlation between the expression levels of prognostic genes and the levels of TIICs were revealed via TIMER.

3.3. Heatmap and volcano plot analyses

A heatmap of immune-cell proportions and DEGs for ovarian serous adenocarcinoma patients stratified by immune scores and stromal scores was generated using the pheatmap2 package in R software. Volcano plots of DEGs were generated using the gplots package in R software.

3.4. Survival analysis

To identify potential prognostic genes, Kaplan-Meier survival and a univariate Cox model were was assessed using R software to investigate the correlation between immune/stromal scores and patent overall survival (OS). Kaplan-Meier plots were re-generated using GraphPad Prism5 software.

3.5. Functional analysis

Gene Ontology (GO) and KEGG analysis of genes was performed using DAVID. A false discovery rate (FDR) < 0.05 was considered the cut-off. Results of the GO enrichment analysis were visualized by ggplot2 and GraphPad Prism5. The protein-protein interaction (PPI) network was determined from the STRING database (https://string-db.org/) and remodeled using Cytoscape software.

3.6. Statistical analysis

One-way analysis of variance was used to compare the immune and stromal scores in different groups using GraphPad Prism 5. The validation of TIICs between high-score and low-score groups were studied using Wilcoxon test. For all statistical tests, p-value < 0.05 were considered as statistically significant.

4. Results

4.1. Immune and stromal scores among ovarian serous adenocarcinoma patients

Based on the ESTIMATE algorithm, the immune scores of 469 ovarian serous adenocarcinoma patients were distributed between -1498.58 and 2774.16, and the stromal scores ranged from -1988.05 to -1837.43. To further analyze the association between ESTIMAE scores and clinicopathological features, we downloaded the gene expression profile and clinical characteristics of the 469 patients from TCGA database. As shown in Table 1, the histological types among 469 OC patients were serous adenocarcinoma, among which accurate molecular classification of subtypes was successfully carried out for 281 patients: proliferative 22.420% (63/281), immunoreactive 28.470% (80/281), mesenchymal 22.776% (64/281), and differentiated 26.335% (74/281). The prognosis of the immunoreactive subtype was relatively better than that of the other three subtypes, and its immune scores were the highest, followed by the stromal scores (Figure 1A and B). The immune and stromal scores were not significantly correlated with the clinical stage (Figure 1C and D).

Figure 1. Immune scores and stromal scores are associated with the subtypes of ovarian serous adenocarcinoma. Distribution of immune scores in different ovarian serous adenocarcinoma subtypes (n=469, p<0.001). B. Distribution of stromal scores in different ovarian serous adenocarcinoma subtypes (n=469, p<0.001). C. Distribution of immune scores in different clinical stages. D. Distribution of stromal scores in different clinical stages.
Table 1. Clinical and pathological characteristics of patients with Serous cystadenocarcinoma
CharacteristicsNumber of SubjectsPercent
Sex
● Female469100
Age
● < 6024852.878
● ≥ 6022147.122
Histological type
● Serous cystadenocarcinoma469100
Histological subtype
● Differentiated6313.433
● Immunoreactive8017.058
● Mesenchymal6413.646
● Proliferative7415.778
● Unknown18840.085
Stage
● II255.330
● III36577.825
● IV7515.991
● Unknown40.853

4.2. Immune cell abundance in ovarian serous adenocarcinoma

To verify the accuracy of the ESTIMATE scores, we determined the abundance of six types of immune cells, ie, B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells, of the 469 patients via TIMER (https://cistrome.shinyapps.io/timer/). Based on the median immune/stromal scored, patients were divided segregated into high-score and low-score groups. The heatmap of immune cell abundance indicated that immune cell infiltration is significantly higher in the high-score than that in low-score group, regardless of the immune or stromal scores (Figure 2A and B), indicating that ESTIMATE scores can accurately assess immune cell abundance. Immune cell infiltration in ovarian serous adenocarcinoma patients was as follows: dendritic cells > CD8 + T cells > CD4 + T cells > neutrophils > B cells > macrophages (Figure 2C and D). Further analysis revealed that high levels of dendritic cells and CD4+T cells were positive prognostic factors; in particular, dendritic cell infiltration was significantly positively correlated with the OS ( Figure 2E).

Figure 2. The abundance and infiltration of six types of immune cells in ovarian serous adenocarcinoma and its association with patient prognosis.
Patients were divided into two groups on the basis of their immune/stromal scores ((high score, n=235) vs. (low score, n=234)). Red indicates immune cells with higher proportions and blue indicates immune cells with lower proportions. A-B. Heatmaps of immune-cell proportions of ovarian serous adenocarcinoma patients stratified by immune or stromal scores. C-D. Immune cell infiltration in ovarian serous adenocarcinoma. E. The overall survival of ovarian serous adenocarcinoma patients stratified by the infiltration of immune cells.

4.3. DEGs associated with the tumor microenvironment in ovarian serous adenocarcinoma

To investigate the correlation between global gene expression profiles and the tumor microenvironment in ovarian serous adenocarcinoma, we analyzed Affymetrix microarray data of 469 ovarian serous adenocarcinoma patients from TCGA. Based on a comparative analysis of immune scores, 166 DEGs were identified, of which 161 were upregulated and 5 were downregulated in the high-score group in comparison with the low-score group (Figure 3A). Similarly, based on the stromal scores, 165 DEGs were identified, of which 163 were upregulated and 2 were downregulated in the high-score group (Figure 3B).

Figure 3. Comparison of gene expression profiles with immune and stromal scores in ovarian serous adenocarcinoma.
A-B. Volcano plot of differentially expressed genes (DEGs) in ovarian serous adenocarcinoma patients stratified by immune or stromal scores (p<0.05, fold change >2). Upregulated genes are indicated in red; downregulated genesare indicated in green.

4.4. GO functional analysis of DEGs

Furthermore, 87 intersection DEGs in the stromal and immune score groups were identified (Figure 4A). Functional enrichment of the 87 intersection genes was further carried out. The top 10 GO terms including biological processes, cellular components, and molecular functions are enlisted (Figure 4B-D).

Figure 4. GO functional analysis of intersection DEGs in the stromal and immune score groups.A. Venn diagram analysis of DEGs in the stromal and immune score groups. B-D. Gene Ontology analysis of identical DEGs in the stromal and immune score groups. p <0.05.

4.5. Prognostic potential of DEGs in ovarian serous adenocarcinoma

We further investigated whether the expression of DEGs was correlated with the prognosis of ovarian serous adenocarcinoma patients. Through the Kaplan-Meier survival and a univariate Cox model, we obtained 21 and 31 DEGs, respectively (39 DEGs in total), which significantly influenced the prognosis of ovarian serous adenocarcinoma patients, including 13 intersection genes (Figure 5A). Moreover, among the 13 intersection genes, 11 were positively associated with a better prognosis (Figure 5B-N).

Figure 5. Differentially expressed genes (DEGs) associated with overall survival(days). Venn diagram of DEGs associated with overall survival on the Log-rank test and Cox regression analysis (p < 0.05). B-N. Kaplan-Meier survival curves for identical genes associated with overall survival on both the Log-rank test and Cox regression analysis.

4.6. Correlation between DEGs and immune cell infiltration

Considering the association of the OS with the abundance of dendritic cells in ovarian serous adenocarcinoma, we investigated the correlation between DEGs and immune cell infiltration via TIMER. As expected, 12 of 13 intersection genes were positively correlated with dendritic cell infiltration (Table 2). The reliability of the prognostic values of these genes was further verified. Four genes (GBP2, ALOX5AP, CD2, and IDO1) were significantly positively correlated with infiltrating dendritic cells in ovarian serous adenocarcinoma (Correlation coefficient>0.4, p<0.01; Figure 6A-D).

Figure 6. Correlation between prognosis-related genes and immune cell infiltration. Expression levels of 4 prognosis-related and immune-related genes are correlated with dendritic cell abundance in ovarian serous adenocarcinoma (Cor>0.4, p<0.05). A-D. GBP2/ALOX5AP/CD2/IDO1 expression is significantly positively associated with dendritic cell infiltration levels.
Table 2. Correlation of DEGs expression with immune infiltration level
GeneB CellCD8+ T CellCD4+ T CellMacrophageNeutrophilDendritic Cell
Cor 1pCor 1pCor 1pCor 1pCor 1pCor 1p
CXCL110.27071.65E-090.35598.78E-160.22061.05E-060.11630.01080.46921.21E-270.39522.15E-19
GBP10.24594.81E-080.34428.43E-150.19032.70E-050.02290.61690.43786.79E-240.37124.00E-17
CXCL130.11020.01570.33922.19E-140.30844.88E-120.05840.20140.37123.97E-170.35776.17E-16
UBD0.21252.63E-060.29693.16E-110.23601.68E-07-0.04780.29610.36232.48E-160.36381.83E-16
GBP20.28691.50E-100.40343.29E-200.21142.96E-060.05930.19470.50313.70E-320.49495.07E-31
CXCL90.19891.14E-050.40155.15E-200.26822.37E-090.02540.57890.33802.72E-140.38977.42E-19
ALOX5AP0.30271.25E-110.37302.72E-170.29942.12E-110.33792.75E-140.57402.06E-430.53211.89E-36
TAP10.26932.02E-090.33643.66E-140.20287.52E-060.00120.97940.42769.20E-230.38203.98E-18
C20.23212.73E-070.22754.72E-070.23791.33E-070.08650.05810.34883.55E-150.31996.98E-13
NUAK1-0.17161.59E-04-0.08240.07130.00870.84960.17679.93E-05-0.02700.5545-0.05460.2321
MMP9-0.01690.71190.05690.21340.36023.73E-16-0.07640.09450.34081.61E-140.36073.43E-16
CD20.24992.89E-080.58601.33E-450.31996.93E-130.16100.00040.48942.86E-300.52344.13E-35
IDO10.25137.20E-050.47354.88E-150.17130.0073-0.03370.60020.49322.31E-160.41202.04E-11
1 Correlation coefficient

4.7. Functional analysis of prognostic genes

To further understand the association and function of the prognosis-related genes, we established a protein-protein interaction (PPI) network, using the STRING tool. With a comprehensive score of 0.25 as the cutoff, 39 prognostic genes were identified. Thirty-three gene nodes and 135 edges were obtained. CXCL9, CXCL10, CD74, GZMB, IDO1, MMP9, and PSMB9 displayed high values for the degree of connectivity, indicating that they are the core genes in this network (Figure 7A). Further functional enrichment analysis (GO/KEGG) indicated that these prognostic genes are strongly associated with the immune response (Figure 7B-C).

Figure 7. Functional analysis of prognosis-related and immune-related genes. A. Protein-protein interaction (PPI) networks of differentially expressed genes. The color of a node in the PPI network reflects the log (FC) value, and the size of node indicates the number of interacting proteins with the designated protein. B. KEGG analysis of prognosis-related and immune-related genes. C. Gene Ontology analysis of prognosis-related and immune-related genes.

4.8. Verification of prognostic genes in the GEO database

To avoid a bias during analysis of the TCGA cohort, we used the GEO database (GSE9891, GSE26712, and GSE17260) as a validation dataset. Twenty genes were correlated with the prognosis of OC patients, including the following 6 core genes: CXCL9, CXCL10, CD74, GZMB, MMP9, and PSMB9 (Figure 8A-F).

Figure 8. Verification of prognosis-related and immune-related genes from The Cancer Genome Atlas and Gene Expression Omnibus (GEO) databases. F. Kaplan-Meier survival curves of differentially expressed genes in ovarian serous adenocarcinoma in the GEO database (P<0.05).

5. Discussion

Recent studies have reported remarkable advancements in cancer immunotherapy targeting the tumor microenvironment, including therapies targeting novel immune checkpoints (e.g, PD-1, CTLA-4, and IDO1) or immune cells (NK, Treg) (13-14), however, the therapeutic effects are not satisfactory. One of the factors contributing to the unfavorable curative effect is the poor selection of target genes. Hence, the identification of new biomarkers closely associated with patient prognosis may reveal strategies to improve the response rate of immunotherapy. Considering the significance of the TME in tumorigenesis, the present study potentially provides novel insights into the genes associated with the TME.

ESTIMATE scores have long been considered to assess tumor purity, stromal cell levels, and the immune cell infiltration levels in tumor tissues. ESTIMATE scores are correlated with patient prognosis in several cancers, including breast cancer, (15) glioblastoma, (16-17) and esophageal cancer (18). Furthermore, OC patients in the GEO database with high immune and stromal scores had a longer survival time, suggesting that the tumor microenvironment is closely associated with patient outcomes (19). Similarly, our study shows that both immune and stromal scores are significantly correlated with the molecular subtypes of ovarian serous adenocarcinoma. The immunoreactive subtype displayed the highest immune score, followed by the stromal score. However, high scores indicates increased immune cell infiltration levels, and among six types of infiltrating immune cells, dendritic cells were the most abundant and correlated with a favorable prognosis, indicating that the TME is strongly associated with clinical outcomes in ovarian serous adenocarcinoma.

We further identified 87 DEGs in both the stromal and immune score groups. Consequently, 39 DEGs were found to significantly influence the prognosis of ovarian serous adenocarcinoma patients, including 13 intersection genes. In particular, 11 of 13 intersection DEGs were positively correlated with patient prognosis and dendritic cell infiltration, further affirming their prognostic value. Moreover, the validity of DC vaccines has been previously reported (20-21). However, it remains unclear whether the upregulation of these genes would enhance the effectiveness of DC vaccines.

Furthermore, GO functional analysis of DEGs and prognostic genes revealed that most of these genes are involved in the formation the extracellular matrix and the immune response in the TME, concurrent with previous reports on the role of the TME in solid tumors, indicating that the functions of immune cells and extracellular matrix molecules in constituting the TME in OC are interrelated (9,17). Moreover, several genes potentially playing an important role were identified through PPI network analysis: CXCL9, CXCL10, CD74, GZMB, IDO1, MMP9, and PSMB9.Finally, 20 of 37 identified genes from TCGA were confirmed to be positively associated with OC patient prognosis in the GEO database. Among these 20 genes, 6 key genes identified through PPI analysis were included (CXCL9, CXCL10, CD74, GZMB, MMP9, and PSMB9) and further assessed. CXCL9, CXCL10, and MMP9 are involved in OC pathogenesis or are important in predicting the patient OS. As chemokines induced by inflammatory response, CXCL9 and CXCL10 play an important role in tumorigenesis. CXCL9 and CXCL10 have a robust and independent prognostic value, indicating increasing immune cell infiltration and a tumor-suppressive effect in OC, (22-24) which was also consistent with our results. MMP9 enhances tumor cell migration and invasion in OC, indicating a poor patient prognosis (25-26).

The role of GZMB, CD74, and PSMB9 in OC remains unclear. PSMB9 encodes the immunoproteasome subunit. Proteasomes are a potential target for novel anticancer drugs and chemosensitizers (27). Proteasome inhibitors are reportedly effective in the treatment of OC, indicating that PSMB9 is potentially involved in OC pathogenesis (28) GZMB is associated with autophagy (29) and apoptosis, (30) and its upregulation enhances patient prognosis in colorectal cancer (31) CD74 is associated with patient prognosis in melanoma (32) and acute myeloid leukemia (33) and clinical stages of thyroid cancer (34) and gastric cancer (35). The significance of these three genes in OC has been neglected; however, the present study shows that they are potential biomarkers for ovarian serous adenocarcinoma.

Recently, integrated bioinformatics analysis is getting increasing attention, previous study had investigated the differentially expressed genes in the ovarian cancer samples in comparison with the normal ovarian samples using GEO datasets (36) Unlike this study, our study identified different specific prognostic gene profiles in the TME that also associated with patients’survival and the infiltration of immune cells based on the ESTIAMTE, TCGA and TIMER databases. Moreover, our research is highly focused on the transcriptional profiles of ovarian serous adenocarcinoma rather than on the wide-ranging tumor and non-tumor tissues. Additionally, satisfactory validation efficiency in GEO revealed that our prognostic gene profiles may have its potential for clinical application.

Elucidation of potential genetic changes in tumor cells and the TME would enhance the current understanding of tumor biology. Herein, we focused on differential gene profiles in the TME, which in turn influenced the clinical outcomes in ovarian serous adenocarcinoma patients. These genes potentially provide insights into the mechanisms underlying ovarian serous adenocarcinoma oncogenesis and pathogenesis. Furthermore, the correlation between these genes and immune cell infiltration suggests their potential to predict the immune response rate among ovarian serous adenocarcinoma patients receiving immunotherapy. This study has the following limitations. First, to ensure the accuracy of prognostic markers, we use a higher threshold, thus potentially excluding some potential DEGs. Second, the function and significance of these prognostic markers require further experimental validation.

In conclusion, this study, applying a systems biology approach, provides a more comprehensive understanding of the TME and reveals a set of genes potentially serving as prognostic biomarkers. Further studies of these genes may provide novel insights into the diagnosis and treatment of ovarian serous adenocarcinoma.

6. Acknowledgments

The datasets analyzed during the current study are publicly available from the following online databases: GEO (http://www.ncbi.nlm.nih.gov/geo/); TCGA (https://tcga-data.nci.nih.gov/tcga/); ESTIMATE (https://bioinformatics.mdanderson.org/estimate/); ESTIMATE (https://bioinformatics.mdanderson.org/estimate/); TIMER (https://cistrome.shinyapps.io/timer/); STRING database (https://string-db.org/). This study was fully supported by National Natural Science Foundation of China (81670474), The Digestive Medical Coordinated Development Center of Beijing Hospitals Authority, No. XXT01 and China Population Publicity and Education Center Research and Promotion Project (No. 2017-A001 ). Ruyue Tian conceived the project and wrote the manuscript. Ruyue Tian, Guiping Zhao, Anni Zhou, Huihui Li, Bangwei Cao participated in data analysis, discussion and language editing. Shuilong Guo reviewed the manuscript.

Abbreviations: DEGs: differentially expressed genes; OC: Ovarian cancer; TME: the tumor microenvironment; TIICs: tumor-infiltrating immune cells; OS: overall survival; FDR: false discovery rate
References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68, 394-424 (2018)

    2. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL: Ovarian cancer statistics, 2018. CA Cancer J Clin 68, 284-296 (2018)

    3. Kommoss S, Winterhoff B, Oberg AL, Konecny GE, Wang C, Riska SM, Fan JB, Maurer MJ, April C, Shridhar V, Kommoss F, du Bois A, Hilpert F, Mahner S, Baumann K, Schroeder W, Burges A, Canzler U, Chien J, Embleton AC, Parmar M, Kaplan R, Perren T, Hartmann LC, Goode EL, Dowdy SC, Pfisterer J: Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes. Clin Cancer Res 23, 3794-3801 (2017)

    4. Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, Levanon K, Sougnez C, Tsherniak A, Gomez S, Onofrio R, Gabriel S, Chin L, Zhang N, Spellman PT, Zhang Y, Akbani R, Hoadley KA, Kahn A, Köbel M, Huntsman D, Soslow RA, Defazio A, Birrer MJ, Gray JW, Weinstein JN, Bowtell DD, Drapkin R, Mesirov JP, Getz G, Levine DA, Meyerson M, Cancer Genome Atlas Research Network: Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 123, 517-25 (2013)

    5. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, Matsumura N, Abiko K, Baba T, Yamaguchi K, Ueda A, Hosoe Y, Morita S, Yokode M, Shimizu A, Honjo T, Konishi I: Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol 33, 4015-22 (2015)

    6. Peng J, Hamanishi J, Matsumura N, Abiko K, Murat K, Baba T, Yamaguchi K, Horikawa N, Hosoe Y, Murphy SK, Konishi I, Mandai M: Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. Cancer Res 75, 5034-45 (2015)

    7. Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, Chand V, Gulley JL: Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol 5, 393-401 (2019)

    8. Pasini FS, Zilberstein B, Snitcovsky I, Roela RA, Mangone FR, Ribeiro U, Nonogaki S, Brito GC, Callegari GD, Cecconello I, Alves VA, Eluf-Neto J, Chammas R, Federico MHl: A gene expression profile related to immune dampening in the tumor microenvironment is associated with poor prognosis in gastric adenocarcinoma. J Gastroenterol 49, 1453-66 (2014)

    9. Yang S, Liu T, Nan H, Wang Y, Chen H, Zhang X, Zhang Y, Shen B, Qian P, Xu S, Sui J, Liang G: Comprehensive analysis of prognostic immune-related genes in the tumor microenvironment of cutaneous melanoma. J Cell Physiol 235, 1025-1035 (2019)

    10. Ge P, Wang W, Li L, Zhang G, Gao Z, Tang Z, Dang X, Wu Y: Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of colorectal cancer. Biomed Pharmacother 118, 109228 (2019)

    11. Giraldo NA, Sanchez-Salas R, Peske JD, Vano Y, Becht E, Petitprez F, Validire P, Ingels A, Cathelineau X, Fridman WH: The clinical role of the TME in solid cancer. Br J Cancer 120, 45-53 (2019)

    12. Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, Carter SL, Getz G, Stemke-Hale K, Mills GB, Verhaak RG: Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 4, 2612 (2013)

    13. McCloskey CW, Rodriguez GM, Galpin KJC, Vanderhyden BC: Ovarian Cancer Immunotherapy:Preclinical Models and Emerging Therapeutics. Cancers (Basel) 10, E244 (2018)

    14. Kon E, Benhar I: Immune checkpoint inhibitor combinations: Current efforts and important aspects for success. Drug Resist Updat 10, E244 (2019)

    15. Wang J, Li Y, Fu W, Zhang Y, Jiang J, Zhang Y, Qi X: Prognostic nomogram based on immune scores for breast cancer patients. Cancer Med 8, 5214-5222 (2019)

    16. Chen Q, Han B, Meng X, Duan C, Yang C, Wu Z, Magafurov D, Zhao S, Safin S, Jiang C, Cai J: Immunogenomic analysis reveals LGALS1 contributes to the immune heterogeneity and immunosuppression in glioma. Int J Cancer 145, 517-530 (2019)

    17. Jia D, Li S, Li D, Xue H, Yang D, Liu Y: Mining TCGA database for genes of prognostic value in glioblastoma microenvironment. Aging (Albany NY) 10, 592-605 (2018)

    18. Park S, Joung JG, Min YW, Nam JY, Ryu D, Oh D, Park WY, Lee SH, Choi Y, Ahn JS, Ahn MJ, Park K, Sun JM: Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma. J Immunother Cancer 7, 128 (2019)

    19. Liu W, Ye H, Liu YF, Xu CQ, Zhong YX, Tian T, Ma SW, Tao H, Li L, Xue LC, He HQ: Transcriptome-derived stromal and immune scores infer clinical outcomes of patients with cancer. Oncol Lett 15, 4351-4357 (2018)

    20. Conrad C, Gregorio J, Wang YH, Ito T, Meller S, Hanabuchi S, Anderson S, Atkinson N, Ramirez PT, Liu YJ, Freedman R, Gilliet M: Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells. Cancer Res 72, 5240-9 (2012)

    21. Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Smith L, Nisenbaum HL, Levine BL, Kalos M, Czerniecki BJ, Torigian DA, Powell DJ, Mick R, Coukos G: A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res 19, 4801-15 (2013)

    22. Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, Sun Y, Zhao E, Vatan L, Szeliga W, Kotarski J, Tarkowski R, Dou Y, Cho K, Hensley-Alford S, Munkarah A, Liu R, Zou W: Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527, 249-53 (2015)

    23. Bronger H, Singer J, Windmüller C, Reuning U, Zech D, Delbridge C, Dorn J, Kiechle M, Schmalfeldt B, Schmitt M, Avril S: CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer. Br J Cancer 115, 553-63 (2016)

    24. KAu K, Peterson N, Truesdell P, Reid-Schachter G, Khalaj K, Ren R, Francis JA, Graham CH, Craig AW, Koti M: CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer. Gynecol Oncol 145, 436-445 (2017)

    25. Siu MKY, Jiang YX, Wang JJ, Leung THY, Han CY, Tsang BK, Cheung ANY, Ngan HYS, Chan KKL: Hexokinase 2 Regulates Ovarian Cancer Cell Migration, Invasion and Stemness via FAK/ERK1/2/MMP9/NANOG/SOX9 Signaling Cascades. Cancers (Basel) 11, E813 (2019)

    26. Xu F, Si X, Wang J, Yang A, Qin T, Yang Y: Nectin-3 is a new biomarker that mediates the upregulation of MMP2 and MMP9 in ovarian cancer cells. Biomed Pharmacother 110, 139-144 (2019)

    27. Landis-Piwowar KR, Milacic V, Chen D, Yang H, Zhao Y, Chan TH, Yan B, Dou QP: The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist Updat 9, 263-73 (2006)

    28. Bazzaro M, Lin Z, Santillan A, Lee MK, Wang MC, Chan KC, Bristow RE, Mazitschek R, Bradner J, Roden RB: Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res 14, 7340-7 (2008)

    29. Viry E, Baginska J, Berchem G, Noman MZ, Medves S, Chouaib S, Janji B: Autophagic degradation of GZMB/granzyme B: a new mechanism of hypoxic tumor cell escape from natural killer cell-mediated lysis. Autophagy 10, 173-5(2014)

    30. BenSafta T, Ziani L, Favre L, Lamendour L, Gros G, Mami-Chouaib F, Martinvalet D, Chouaib S, Thiery J: Granzyme B-activated p53 interacts with Bcl-2 to promote cytotoxic lymphocyte-mediated apoptosis. J Immunol 194, 418-28 (2015)

    31. Prizment AE, Vierkant RA, Smyrk TC, Tillmans LS, Nelson HH, Lynch CF, Pengo T, Thibodeau SN, Church TR, Cerhan JR: Cytotoxic T Cells and Granzyme B Associated with Improved Colorectal Cancer Survival in a Prospective Cohort of Older Women. Cancer Epidemiol Biomarkers Prev 26, 622-631 (2017)

    32. Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL, Milton DR, Woodman SE, Prieto VG, Gershenwald, JE, Morton DL, Hoon DS, Grimm EA: Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. Clin Cancer Res 22, 3016-24 (2016)

    33. Ruvolo PP, Hu CW, Qiu Y, Ruvolo VR, Go RL, Hubner SE, Coombes KR, Andreeff M, Qutub AA, Kornblau SM: LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML. EBioMedicine 44, 126-137 (2019)

    34. Cheng SP, Liu CL, Chen MJ, Chien MN, Leung CH, Lin CH, Hsu YC, Lee JJ: CD74 expression and its therapeutic potential in thyroid carcinoma. Endocr Relat Cancer 22, 179-90 (2015)

    35. Zheng YX, Yang M, Rong TT, Yuan XL, Ma YH, Wang ZH, Shen LS, Cui L: CD74 and macrophage migration inhibitory factor as therapeutic targets in gastric cancer. World J Gastroenterol 18, 2253-61 (2012)

    36. Yang X, Zhu S, Li L, Zhang L, Xian S, Wang Y, Cheng Y: Identification of differentially expressed genes and signaling pathways in ovarian cancer by integrated bioinformatics analysis. Onco Targets Ther 11, 1457-1474(2018)

Share and Cite
Ruyue Tian, Guiping Zhao, Anni Zhou, Huihui Li, Bangwei Cao, Shuilong Guo. Prognostic gene profiles in the tumor microenvironment of ovarian serous adenocarcinoma. Frontiers in Bioscience-Landmark. 2020. 26(4); 692-705.